We are live on
!
Find out more
EAM
Exome Asset Management Portfolio holdings
AUM
$193M
1-Year Est. Return
208.51%
This Fund
S&P 500
This Quarter
Est. Return
+14.64%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$193M
AUM Growth
-$15.8M
(-7.6%)
Cap. Flow
-$20.2M
Cap. Flow
% of AUM
-10.45%
Top 10 Holdings %
Top 10 Hldgs %
42.42%
Holding
83
New
23
Increased
5
Reduced
24
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$4.1M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
+$3.95M |
| 3 |
MAZE
Maze Therapeutics
MAZE
|
+$3.91M |
| 4 |
Boston Scientific
BSX
|
+$3.87M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
+$3.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Wave Life Sciences
WVE
|
+$5.49M |
| 2 |
AstraZeneca
AZN
|
+$5.26M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$4.5M |
| 4 |
Immunovant
IMVT
|
+$4.03M |
| 5 |
Praxis Precision Medicines
PRAX
|
+$3.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Praxis Precision Medicines
PRAX
$8.49B
| $14.6M | 7.58% |
45,469
-12,653
| -22% | -$3.91M |
|
2
Cogent Biosciences
COGT
$6.54B
| $10.7M | 5.54% |
278,533
-27,035
| -9% | -$998K |
|
3
Enliven Therapeutics
ELVN
$3.69B
| $8.63M | 4.46% |
220,091
-2,217
| -1% | -$61.4K |
|
4
Ionis Pharmaceuticals
IONS
$8.75B
| $8.26M | 4.27% |
110,064
-6,451
| -6% | -$509K |
|
5
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| $7.66M | 3.96% |
+60,000
| New | +$7.49M |
|
6
Guardant Health
GH
$19.6B
| $7.64M | 3.95% |
82,736
-15,446
| -16% | -$1.55M |
|
7
Cytokinetics
CYTK
$10.7B
| $6.84M | 3.54% |
103,718
-21,031
| -17% | -$1.34M |
|
8
Eli Lilly
LLY
$1.02T
| $6.45M | 3.34% |
7,012
-840
| -11% | -$852K |
|
|
ALMS
9
Alumis Inc
ALMS
$3.57B
| $6.15M | 3.18% |
279,176
-13,074
| -4% | -$327K |
|
10
BridgeBio Pharma
BBIO
$15.8B
| $5.01M | 2.59% |
67,492
-13,231
| -16% | -$959K |
|
11
Vera Therapeutics
VERA
$2.66B
| $4.63M | 2.39% |
114,991
-9,400
| -8% | -$405K |
|
|
12
Insmed
INSM
$23.2B
| $4.36M | 2.25% |
+26,651
| New | +$4.1M |
|
13
Elevance Health
ELV
$82.9B
| $4.3M | 2.22% |
14,677
-2,514
| -15% | -$826K |
|
14
Agios Pharmaceuticals
AGIO
$2.38B
| $4.23M | 2.19% |
125,060
-11,882
| -9% | -$337K |
|
15
United Therapeutics
UTHR
$22.5B
| $4.18M | 2.16% |
7,053
-632
| -8% | -$315K |
|
|
16
MoonLake Immunotherapeutics
MLTX
$1.59B
| $4.01M | 2.08% |
+215,376
| New | +$3.57M |
|
|
17
PUT
Cytokinetics
CYTK
$10.7B
| $3.95M | 2.05% |
+60,000
| New | +$3.81M |
|
18
Natera
NTRA
$37.6B
| $3.73M | 1.93% |
18,650
| – | – |
|
|
19
Rhythm Pharmaceuticals
RYTM
$7.17B
| $3.53M | 1.83% |
+40,581
| New | +$3.95M |
|
20
UnitedHealth
UNH
$383B
| $3.48M | 1.8% |
12,862
+7,027
| +120% | +$2.09M |
|
|
APLS
21
DELISTED
Apellis Pharmaceuticals
APLS
| $3.44M | 1.78% |
85,517
-50,332
| -37% | -$1.08M |
|
22
Verastem
VSTM
$505M
| $3.37M | 1.75% |
636,700
+234,957
| +58% | +$1.45M |
|
23
10x Genomics
TXG
$5.49B
| $3.27M | 1.69% |
154,194
-9,464
| -6% | -$189K |
|
|
24
Boston Scientific
BSX
$65.1B
| $3.03M | 1.57% |
+48,347
| New | +$3.87M |
|
25
Alkermes
ALKS
$8.62B
| $2.97M | 1.54% |
+84,103
| New | +$2.61M |
|
Similar funds
WWC
JHA
TDWM
MUAMU
DF
BW
SCM
CWRP
Exome Asset Management's Q1 2026 Portfolio in Review
As of Q1 2026, Exome Asset Management held 83 positions worth $193M, down 7.6% from $209M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Exome Asset Management withdrew a net $20.2M in Q1 2026, closing 27 positions and reducing 24 holdings. Its most notable exit was Wave Life Sciences, an estimated $5.49M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 97% a quarter earlier.
Against the trend, Exome Asset Management opened a new position in Insmed worth $4.36M.
- Exome Asset Management's largest Q1 2026 buy was Insmed: 26,651 shares worth $4.36M.
- Exome Asset Management added most to UnitedHealth in Q1 2026, an estimated $2.09M increase.
- Exome Asset Management's biggest Q1 2026 reduction was Praxis Precision Medicines, cutting an estimated $3.91M.
- Exome Asset Management fully exited Wave Life Sciences in Q1 2026, selling an estimated $5.49M.
- Exome Asset Management's ten largest holdings make up 42% of its $193M portfolio in Q1 2026.
- Exome Asset Management opened 23 new positions and closed 27 in Q1 2026.
- Exome Asset Management's portfolio value fell 7.6% quarter-over-quarter to $193M.
Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.